|
Quinolones and derivatives
(total related compounds in database) |
| |
|
| 7-[4-[(R)-hydroxy-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]methyl]-3-methylphenyl]-2H-isoquinolin-1-one |
|
Escherichia |
Type 1 fimbriae |
Preclinical (in vivo) |
Mydock-McGrane L, et al. 2016. J Med Chem |
|
| 7-[4-[(R)-hydroxy-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]methyl]-3-methylphenyl]-3,4-dihydro-2H-isoquinolin-1-one |
|
Escherichia |
Type 1 fimbriae |
Preclinical (in vivo) |
Mydock-McGrane L, et al. 2016. J Med Chem |
|
| Virstatin |
|
Acinetobacter
Vibrio |
TFP (Type IV pili)
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro)
Preclinical (in vivo) |
Nait Chabane Y, et al. 2014. BMC Microbiol
Hung DT, et al. 2005. Science |
|
| 1'-butyl-4'-(nitromethyl)-1',4'-dihydro-2,3'-biquinoline |
|
Shigella |
VirF |
Preclinical (in vitro) |
Koppolu V, et al. 2013. Infect Immun |
|
| N-[4-(2-oxo-3,4-dihydro-1H-quinolin-6-yl)-1,3-thiazol-2-yl]-3-(1,3-thiazol-4-ylmethoxy)benzamide |
|
Shigella |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Case HB, et al. 2018. Biochemistry |
|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
|
NOTE: for more interactive and statistic charts, please visit the JavaScript-rich interface of VFDB.
 |
| Back to top |
|
